February 2020
-
02.20.2020 Partnerships Montis Biosciences launched with €8,4 million seed financing and a novel approach to immune-oncology
January 2020
-
01.14.2020 Partnerships Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets -
01.13.2020 Partnerships Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc. -
01.13.2020 Partnerships Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
December 2019
-
12.23.2019 Partnerships BioInvent announces selection of second target and extension of the research collaboration and license agreement with Pfizer Inc. -
12.17.2019 Partnerships Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders -
12.10.2019 Partnerships ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials -
12.04.2019 Partnerships ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
November 2019
-
11.22.2019 Partnerships CeMM enters into research collaboration on expanding the druggable proteome with Pfizer Inc. -
11.13.2019 Partnerships CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.
October 2019
-
10.14.2019 Partnerships ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology